Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.71 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30763136 | 1.00 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7989152 | 0.87 | HDAC1 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28871743 | 0.85 | GAA (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30763162 | 0.84 | HDAC3 (0.74) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL21595522 | 0.84 | HDAC3 (0.74) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL10415432 | 0.84 | GRM4 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2384990 | 0.83 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17136102 | 0.83 | HDAC6 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30416073 | 0.83 | HDAC1 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20302273 | 0.82 | RAB9A (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810597-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS | UNIV OSLO HF (NO) | 2025-11-26 | — | — | EP | disclosed |
| US-11926614-B2 | 1,2,4-triazole derivatives as tankyrase inhibitors | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2024-03-12 | — | — | US | disclosed |
| CN-112469714-B | 1,2, 4-triazole derivatives as tankyrase inhibitors | 奥斯陆大学国家医院 | 2024-03-01 | — | — | CN | disclosed |
| CN-111690947-B | Electrochemical synthesis method of trifluoromethylated aryl amide derivative | 浙江工业大学 | 2021-10-15 | — | — | CN | disclosed |
| EP-3810597-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS | Oslo Universitetssykehus HF (NO) | 2021-04-28 | — | — | EP | disclosed |
| CN-112469714-A | 1,2, 4-triazole derivatives as tankyrase inhibitors | 奥斯陆大学国家医院 | 2021-03-09 | — | — | CN | disclosed |
| CN-111690947-A | Electrochemical synthesis method of trifluoromethylated aryl amide derivative | 浙江工业大学 | 2020-09-22 | — | — | CN | disclosed |
| WO-2019243822-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2019-12-26 | — | — | WO | disclosed |
| CN-105732616-A | Pyrrolopyridine compounds containing biaryl amide structure, preparation method and applications thereof | 江西科技师范大学 | 2016-07-06 | — | — | CN | disclosed |
| CN-105153026-A | Biaryl amide structure containing sorafenib derivative as well as preparation method and applications thereof | UNIV JIANGXI NORMAL SCI & TECH | 2015-12-16 | — | — | CN | disclosed |
| EP-1611096-A4 | BENZAMIDE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1611096-A2 | BENZAMIDE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co. Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087048-A2 | BENZAMIDE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO. INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-4950762-A | ANTIULCER AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-08-21 | — | — | US | disclosed |
| US-4886821-A | 2-pyridinecarbothioamides and pharmaceutical compositions comprising the same useful as anti ulcer agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926614-B2 | 1,2,4-triazole derivatives as tankyrase inhibitors | GBA3, CBR3, TECR | HDAC3 1635/4885HDAC4 3957/4885HDAC1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.